Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Teresa Rasalan, Margaret K. Callahan(Cornell University), Shigehisa Kitano(The Cancer Institute Hospital), Christopher A. Barker(Cornell University), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Ramon Chua(Ludwig Cancer Research), James P. Allison(The University of Texas MD Anderson Cancer Center), Erika Ritter(Ludwig Cancer Research), Matthew Adamow(Memorial Sloan Kettering Cancer Center), Sacha Gnjatic(Tisch Hospital), Christine Sedrak(Ludwig Cancer Research), Brenna Benson(Colorado State University), Zhenyu Mu, Yoshiya Yamada(Memorial Sloan Kettering Cancer Center), Jianda Yuan, Arvin Yang(Bristol-Myers Squibb (United States)), Samuel Rosner(State University of New York), Ruth-Ann Roman(Memorial Sloan Kettering Cancer Center), Achim A. Jungbluth(Gynecologic Oncology Group)
Cited by 2,060
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k